The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare
The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare
复制标题
DOI：
10.1257/pol.20160094
复制
发表时间：
2018-02-01
影响因子：
5.3
通讯作者：
Carey, Colleen
中科院分区：
文献类型：
--
作者：
Buchmueller, Thomas C.;Carey, Colleen
滥用处方阿片类药物在美国已成为一种严重的流行病。作为回应，各州实施了处方药监测计划（PDMP），记录患者的阿片类药物处方史。虽然很少有供应商参与早期的系统，但各州最近开始要求供应商在某些情况下访问PIPE。我们发现，“必须访问”PDMP显着减少医疗保险D部分的滥用措施。相比之下，我们发现，没有这样的规定的PDMP没有效果。我们发现，当提供者被要求在广泛的情况下，而不仅仅是在他们可疑的情况下访问PIPs时，影响更大。
The misuse of prescription opioids has become a serious epidemic in the United States. In response, states have implemented Prescription Drug Monitoring Programs (PDMPs), which record a patient's opioid prescribing history. While few providers participated in early systems, states have recently begun to require providers to access the PDMP under certain circumstances. We find that "must access" PDMPs significantly reduce measures of misuse in Medicare Part D. In contrast, we find that PDMPs without such provisions have no effect. We find stronger effects when providers are required to access the PDMP under broad circumstances, not only when they are suspicious.